Kourosh Shahraki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kourosh Shahraki has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Khalil Ghasemi Falavarjani
Eye Research Center, The Five Senses Institute, Rassoul Akram Hospital, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
2 shared publications Kianoush Shahraki
Department of Ophthalmology, Alzahra Eye Hospital, Zahedan University of Medical Sciences, Zahedan, Iran
2 shared publicationsParia Ghasemi Boroumand
ENT, Head and Neck Research Center and Department, Iran University of Medical Science, Tehran, Iran
2 shared publications- Roghayeh Sheervalilou
Zahedan University of Medical Sciences
2 shared publications - Abdollah Amirfarhangi
Shahid Rajaee Hospital, Iran University of Medical Sciences, Tehran, Iran
1 shared publication Ali Makateb
Department of Ophthalmology, AJA University of Medical Sciences, Tehran, Iran
1 shared publication
Latest Publications
- 1 February 2024
- Published by Taylor & Francis in Current Eye Research
- Vol. 49 (6) , 551-564
The Traces of Dysregulated lncRNAs-Associated ceRNA Axes in Retinoblastoma: A Systematic Scope Review
Long non-coding RNAs are an essential component of competing endogenous RNA regulatory axes and play their role by sponging microRNAs and interfering with the regulation of gene expression. Because of the broadness of competing endogenous RNA interaction networks, they may help investigate treatment targets in complicated disorders. This study performed a systematic scoping review to assess verified loops of competing endogenous RNAs in retinoblastoma, emphasizing the competing endogenous RNAs axis related to long non-coding RNAs. We used a six-stage approach framework and the PRISMA guidelines. A systematic search of seven databases was done to locate suitable papers published before February 2022. Two reviewers worked independently to screen articles and collect data. Out of 363 records, fifty-one articles met the inclusion criteria, and sixty-three axes were identified in desired articles. The majority of the research reported several long non-coding RNAs that were experimentally verified to act as competing endogenous RNAs in retinoblastoma: XIST/NEAT1/MALAT1/SNHG16/KCNQ1OT1, respectively. At the same time, around half of the studies investigated unique long non-coding RNAs. Understanding the many features of this regulatory system may aid in elucidating the unknown etiology of Retinoblastoma and providing novel molecular targets for therapeutic and clinical applications.
- 1 February 2024
- Published by Taylor & Francis in Current Eye Research
- Vol. 49 (6) , 551-564
The Traces of Dysregulated lncRNAs-Associated ceRNA Axes in Retinoblastoma: A Systematic Scope Review
Long non-coding RNAs are an essential component of competing endogenous RNA regulatory axes and play their role by sponging microRNAs and interfering with the regulation of gene expression. Because of the broadness of competing endogenous RNA interaction networks, they may help investigate treatment targets in complicated disorders. This study performed a systematic scoping review to assess verified loops of competing endogenous RNAs in retinoblastoma, emphasizing the competing endogenous RNAs axis related to long non-coding RNAs. We used a six-stage approach framework and the PRISMA guidelines. A systematic search of seven databases was done to locate suitable papers published before February 2022. Two reviewers worked independently to screen articles and collect data. Out of 363 records, fifty-one articles met the inclusion criteria, and sixty-three axes were identified in desired articles. The majority of the research reported several long non-coding RNAs that were experimentally verified to act as competing endogenous RNAs in retinoblastoma: XIST/NEAT1/MALAT1/SNHG16/KCNQ1OT1, respectively. At the same time, around half of the studies investigated unique long non-coding RNAs. Understanding the many features of this regulatory system may aid in elucidating the unknown etiology of Retinoblastoma and providing novel molecular targets for therapeutic and clinical applications.
- 7 August 2023
- Published by Taylor & Francis in Expert Review of Molecular Diagnostics
- Vol. 23 (9) , 753-769
Promotor methylation in ocular surface squamous neoplasia development: epigenetics implications in molecular diagnosis
IntroductionCancer is heavily influenced by epigenetic mechanisms that include DNA methylation, histone modifications, and non-coding RNA. A considerable proportion of human malignancies are believed to be associated with global DNA hypomethylation, with localized hypermethylation at promoters of certain genes.Area coveredThe present review aims to emphasize on recent investigations on the epigenetic landscape of ocular surface squamous neoplasia, that could be targeted/explored using novel approaches such as personalized medicine.Expert opinionWhile the former is thought to contribute to genomic instability, promoter-specific hypermethylation might facilitate tumorigenesis by silencing tumor suppressor genes. Ocular surface squamous neoplasia, the most prevalent type of ocular surface malignancy, is suggested to be affected by epigenetic mechanisms, as well. Although the exact role of epigenetics in ocular surface squamous neoplasia has mostly been unexplored, recent findings have greatly contributed to our understanding regarding this pathology of the eye.
- 7 August 2023
- Published by Taylor & Francis in Expert Review of Molecular Diagnostics
- Vol. 23 (9) , 753-769
Promotor methylation in ocular surface squamous neoplasia development: epigenetics implications in molecular diagnosis
IntroductionCancer is heavily influenced by epigenetic mechanisms that include DNA methylation, histone modifications, and non-coding RNA. A considerable proportion of human malignancies are believed to be associated with global DNA hypomethylation, with localized hypermethylation at promoters of certain genes.Area coveredThe present review aims to emphasize on recent investigations on the epigenetic landscape of ocular surface squamous neoplasia, that could be targeted/explored using novel approaches such as personalized medicine.Expert opinionWhile the former is thought to contribute to genomic instability, promoter-specific hypermethylation might facilitate tumorigenesis by silencing tumor suppressor genes. Ocular surface squamous neoplasia, the most prevalent type of ocular surface malignancy, is suggested to be affected by epigenetic mechanisms, as well. Although the exact role of epigenetics in ocular surface squamous neoplasia has mostly been unexplored, recent findings have greatly contributed to our understanding regarding this pathology of the eye.
- Retracted
- 6 November 2015
- Published by Springer Nature in Tumor Biology
- Vol. 37 (12) , 16395
RETRACTED ARTICLE: The expression of mitochondrial complexes I and III correlates with prognosis or diagnosis in retinoblastoma: immunohistochemical and histopathological parameters
- 6 November 2015
- Published by Springer Nature in Tumor Biology
- Vol. 37 (12) , 16395
RetractedRETRACTED ARTICLE: The expression of mitochondrial complexes I and III correlates with prognosis or diagnosis in retinoblastoma: immunohistochemical and histopathological parameters
- 1 August 2014
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 49 (4) , 395-398
Spontaneous closure of traumatic macular holes
- 1 August 2014
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 49 (4) , 395-398
Spontaneous closure of traumatic macular holes
- 1 August 2012
- Published by Elsevier in Journal of American Association for Pediatric Ophthalmology and Strabismus
- Vol. 16 (4) , 392-393
Central retinal artery occlusion in Crohn disease
- 1 August 2012
- Published by Elsevier in Journal of American Association for Pediatric Ophthalmology and Strabismus
- Vol. 16 (4) , 392-393
Central retinal artery occlusion in Crohn disease